Send to

Choose Destination
Heart Fail Clin. 2018 Jan;14(1):27-39. doi: 10.1016/j.hfc.2017.08.004.

N-Terminal B-type Natriuretic Peptide in Heart Failure.

Author information

Cardiovascular Research Institute, National University of Singapore, National University Heart Centre, 1E Kent Ridge Road, NUHS Tower Block 9th Floor (Cardiology), Singapore 129788, Singapore; Christchurch Heart Institute, University of Otago, Riccarton Avenue, Christchurch 8014, New Zealand. Electronic address:


Plasma amino-terminal pro-B-type natriuretic peptide (NT-proBNP) is a guideline-mandated biomarker in heart failure (HF). Used as an inclusion criterion for therapeutic trials, NT-proBNP enriches trial populations and is a valid surrogate endpoint. Its diagnostic performance is best validated in acute decompensated HF (ADHF). NT-proBNP offers prognostic information independent of standard clinical predictors and refines risk stratification. With the advent of combined angiotensin 2 type 1 receptor blockade and neprilysin inhibition (ARNI) NT-proBNP retains its relationship to cardiac status and is the marker of choice in assessment of possible ADHF and in serial monitoring of HF patients receiving ARNI treatment.


Diagnosis; Heart failure; Monitoring; NT-proBNP; Prognosis

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center